232 related articles for article (PubMed ID: 24876749)
1. Telomere and telomerase in chronic liver disease and hepatocarcinoma.
Carulli L; Anzivino C
World J Gastroenterol; 2014 May; 20(20):6287-92. PubMed ID: 24876749
[TBL] [Abstract][Full Text] [Related]
2. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
3. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis.
Miura N; Horikawa I; Nishimoto A; Ohmura H; Ito H; Hirohashi S; Shay JW; Oshimura M
Cancer Genet Cytogenet; 1997 Jan; 93(1):56-62. PubMed ID: 9062581
[TBL] [Abstract][Full Text] [Related]
4. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma.
Lechel A; Manns MP; Rudolph KL
J Hepatol; 2004 Sep; 41(3):491-7. PubMed ID: 15336455
[No Abstract] [Full Text] [Related]
5. Telomere shortening as genetic risk factor of liver cirrhosis.
Carulli L
World J Gastroenterol; 2015 Jan; 21(2):379-83. PubMed ID: 25593453
[TBL] [Abstract][Full Text] [Related]
6. The role of telomeres and telomerase in cirrhosis and liver cancer.
Nault JC; Ningarhari M; Rebouissou S; Zucman-Rossi J
Nat Rev Gastroenterol Hepatol; 2019 Sep; 16(9):544-558. PubMed ID: 31253940
[TBL] [Abstract][Full Text] [Related]
7. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
8. Telomeres and telomerase: a dual role in hepatocarcinogenesis.
Satyanarayana A; Manns MP; Rudolph KL
Hepatology; 2004 Aug; 40(2):276-83. PubMed ID: 15368430
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
10. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
Falleti E; Fabris C; Cmet S; Cussigh A; Bitetto D; Fontanini E; Fornasiere E; Bignulin S; Fumolo E; Bignulin E; Pirisi M; Toniutto P
Liver Int; 2011 Sep; 31(8):1137-43. PubMed ID: 21745286
[TBL] [Abstract][Full Text] [Related]
11. Telomeres, telomerase and HCC: the long and the short of it.
Erlitzki R; Minuk GY
J Hepatol; 1999 Nov; 31(5):939-45. PubMed ID: 10580594
[No Abstract] [Full Text] [Related]
12. Cause-specific telomere factors deregulation in hepatocellular carcinoma.
El Idrissi M; Hervieu V; Merle P; Mortreux F; Wattel E
J Exp Clin Cancer Res; 2013 Sep; 32(1):64. PubMed ID: 24020493
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease.
Kojima H; Yokosuka O; Imazeki F; Saisho H; Omata M
Gastroenterology; 1997 Feb; 112(2):493-500. PubMed ID: 9024303
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma.
Zhang C; Guo X; Jiang G; Zhang L; Yang Y; Shen F; Wu M; Wei L
Int J Cancer; 2008 Sep; 123(5):998-1004. PubMed ID: 18546260
[TBL] [Abstract][Full Text] [Related]
15. Telomeric 3' overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma.
Lee JE; Oh BK; Choi J; Park YN
Int J Cancer; 2008 Jul; 123(2):264-272. PubMed ID: 18449889
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of PinX1 in human hepatocellular carcinoma.
Oh BK; Chae KJ; Park C; Park YN
Oncol Rep; 2004 Oct; 12(4):861-6. PubMed ID: 15375513
[TBL] [Abstract][Full Text] [Related]
17. Genetic diagnostic test of hepatocellular carcinoma by telomerase catalytic subunit mRNA.
Wada E; Hisatomi H; Moritoyo T; Kanamaru T; Hikiji K
Oncol Rep; 1998; 5(6):1407-12. PubMed ID: 9769378
[TBL] [Abstract][Full Text] [Related]
18. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression of hepatomas and circulating telomerase and its clinical values.
Wu W; Yao DF; Qiu LW; Wu XH; Yao M; Su XQ; Zou L
Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):544-9. PubMed ID: 16286259
[TBL] [Abstract][Full Text] [Related]
20. Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length.
Cao H; Zhai Y; Ji X; Wang Y; Zhao J; Xing J; An J; Ren T
Cancer Sci; 2020 Aug; 111(8):2789-2802. PubMed ID: 32357278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
